New Search

If you are not happy with the results below please do another search

1 search result for:

1

Phico Therapeutics awarded up to $18.2 million to advance SASPject antibacterial therapy through Phase 1 clinical trials

Phico Therapeutics, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to US$18.2 million from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research.